Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-26,340
Closed -$1.9M 107
2024
Q4
$1.9M Buy
26,340
+8,308
+46% +$649K 0.25% 106
2024
Q3
$1.47M Buy
+18,032
New +$1.44M 0.34% 108
2023
Q3
Sell
-8,604
Closed -$697K 148
2023
Q2
$697K Sell
8,604
-4,401
-34% -$360K 0.35% 107
2023
Q1
$1.05M Buy
13,005
+1,700
+15% +$137K 0.56% 71
2022
Q4
$846K Sell
11,305
-255
-2% -$18.2K 0.55% 81
2022
Q3
$745K Sell
11,560
-849
-7% -$58.8K 0.51% 90
2022
Q2
$860K Sell
12,409
-10,498
-46% -$779K 0.53% 77
2022
Q1
$1.76M Buy
+22,907
New +$1.65M 0.59% 58
2017
Q3
Sell
-6,131
Closed -$278K 103
2017
Q2
$278K Buy
6,131
+3,138
+105% +$139K 1.08% 18
2017
Q1
$127K Buy
2,993
+1,408
+89% +$57.4K 1.05% 31
2016
Q4
$64K Buy
+1,585
New +$61.2K 1.07% 25

Other funds holding HOLX

Abacus FCF Advisors's HOLX Position: Q1 2025 in Review

Abacus FCF Advisors sold out of Hologic (HOLX) in Q1 2025, closing a stake of 26,340 shares — an estimated $1.9M sold.

Abacus FCF Advisors first reported a position in HOLX in Q4 2016 and held it in 11 quarters. The position peaked at $1.9M in Q4 2024. 705 funds tracked by Wall St. Rank hold HOLX as of Q1 2025.

  • Abacus FCF Advisors reported no remaining Hologic position as of Q1 2025 after selling out during the quarter.
  • Abacus FCF Advisors sold 26,340 Hologic shares in Q1 2025, an estimated $1.9M.
  • Abacus FCF Advisors first reported a position in Hologic in Q4 2016 and held it in 11 quarters.
  • Abacus FCF Advisors's Hologic position peaked at $1.9M in Q4 2024.
  • 705 funds tracked by Wall St. Rank held Hologic as of Q1 2025.

Based on Abacus FCF Advisors's 13F filing for Q1 2025, filed 15 Apr 2025.